RxDoctor Payments Data

Conan Tu, MD

Internal Medicine · Massapequa, NYNPI 1083794440

Payments from drug & device makers

$319,788in general payments, 2019–2025

Across 958 payments — averaging $333.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$173K
  • Sanofi US Services Inc.$25K
  • Novo Nordisk$25K
  • Sanofi$23K
  • Abbott$22K
  • Boehringer Ingelheim$10K
  • plus $42K from 54 others

What the payments were for

  • Consulting fees$85,53527%
  • Speaking & faculty fees$150,58347%
  • Travel & lodging$35,51311%
  • Food & beverage$48,15115%
  • Education$60%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi-aventis U.S. LLC154$172,553
Sanofi US Services Inc.5$25,403
Novo Nordisk73$25,323
Sanofi11$22,776
Abbott78$22,343
Boehringer Ingelheim69$9,540
AstraZeneca66$9,100
Insulet Corporation14$4,324
Amgen77$4,317
Lilly USA, LLC47$2,028
Madrigal Pharmaceuticals7$2,024
Eli Lilly1$1,950
Biohaven Pharmaceuticals, Inc.10$1,823
Cvrx, Inc.11$1,536
Boston Scientific19$1,513
Johnson & Johnson22$1,248
Amarin Pharma, Inc.24$943
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)18$891
Xeris Pharmaceuticals, Inc.17$837
GSK14$834
Pfizer34$797
Intuity Medical Inc10$671
Esperion Therapeutics, Inc.8$669
Merck21$608
Axsome Therapeutics, Inc.10$504
BETA Bionics, Inc.9$495
Teva Pharmaceuticals USA, Inc.13$430
Corcept Therapeutics5$412
Medtronic7$355
Bayer8$330
Eisai Inc.6$325
Novartis10$295
AbbVie(2 entities)12$277
Mannkind Corporation6$212
Dexcom, Inc.4$194
Alnylam Pharmaceuticals Inc.3$157
Heartflow, Inc.1$140
Amneal Pharmaceuticals LLC6$139
Tandem Diabetes Care, Inc.5$136
Ipsen Biopharmaceuticals, Inc1$125
Novo Nordisk AS1$125
Phathom Pharmaceuticals, Inc.1$122
Alkermes, Inc.1$114
DJO, LLC1$104
Daiichi Sankyo Inc.5$103
Recordati_rare_diseases_inc.4$97
Exact Sciences4$80
Ascendis Pharma Endocrinology Inc3$68
IBSA Pharma Inc.3$49
Renalytix AI, Inc.2$45
Amryt Pharma Holdings Ltd2$39
Sanofi Pasteur Inc.2$38
Medicomp Inc1$34
Averitas Pharma Inc.1$26
Neurocrine Biosciences, Inc.1$23
Astellas Pharma US Inc1$23
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$23
Regeneron Healthcare Solutions, Inc.1$20
Insightec,inc1$20
Biohaven Pharmaceutical Holding Company Ltd.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$319,788 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$232,176
Medicare patients
362
Services billed
5,751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide321$431,522
OzempicSemaglutide157$240,953
RybelsusSemaglutide59$111,380
TrulicityDulaglutide52$102,928
FarxigaDapagliflozin Propanediol77$101,908
KerendiaFinerenone56$75,801
JardianceEmpagliflozin45$63,599
Soliqua 100-33Insulin Glargine/Lixisenatide39$41,994
SynjardyEmpagliflozin/Metformin Hcl22$32,895
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$29,049
Repatha SureclickEvolocumab18$23,825
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$19,901
XareltoRivaroxaban20$19,710
Synjardy XrEmpagliflozin/Metformin Hcl12$19,432
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/714$18,305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$2,028$534,450373 claims
Novo NordiskOzempic, Rybelsus$25,323$352,332216 claims
AstraZenecaFarxiga, Breztri Aerosphere$9,100$130,957105 claims
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr$9,540$115,92679 claims
BayerKerendia$330$75,80156 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$172,553$41,99439 claims
Johnson & JohnsonXarelto$1,248$19,71020 claims
Axsome Therapeutics, Inc.Auvelity$504$15,17515 claims
NovartisEntresto$295$12,47214 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$139$2,309122 claims
AbbVieSynthroid$277$1,99142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Massapequa

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →